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Information S1: TaqMan®  Array Human MicroRNA Cards for discovery and miRNA selection for 
validation. 
As described in Materials and methods, TaqMan®  Array Human MicroRNA A+B Cards Set v3.0 
(Thermo Fisher Scientific, Waltham, MA, USA; Cat. No: 4444913) were used in the first step for the 
identification of differentially expressed miRNAs in primary RCC tissue samples depending on the 
response status to TKIs. In total, 754 human miRNAs and 4 snRNAs as multi-controls can be 
determined on these two microfluidic cards (A and B). For that purpose, two RNA sample pools 
consisting of equal RNA aliquots from ten sensitive (responders) and ten resistant (non-responders) 
patients to the sunitinib treatment were prepared. A multiplexed cDNA synthesis was performed. 
One µg RNA per three µL RNA pool was reverse-transcribed with components of the TaqMan 
MicroRNA Reverse Transcription Kit (Thermo Fisher; Cat. No. 4366596) and the Megaplex RT 
Primers, Human Pools Set v3.0 (Cat. No. 4444745) with pool A v2.1 and pool B v3.0. Tubes with a 
final megaplexed RT reaction volume of 7.5 µL were incubated in a Block Thermal cycler (Biometra, 
Göttingen, Germany) according to the Megaplex Pools Protocol without pre-amplification step 
(Thermo Fisher; PN 4399721). Then, six µL of the megaplex-pool-specific cDNAs were mixed with 
TaqMan®  Universal PCR Master Mix, No AmpErase®  UNG, 2x (Cat. No. 4364343) and nuclease-free 
water (5Prime, Hamburg, Germany, Cat. No. 2500000) to a final volume of 900 µL. Each of the 8 ports 
of the TaqMan MicroRNA array card was filled with 100 µL PCR reaction mix. After array 
centrifugation and sealing, the arrays were measured on the real-time PCR system ViiA7 (Thermo 
Fisher Scientific) under default thermal-cycling conditions for the 384 well TaqMan microRNA array 
cards. Cq values were generated by the SDS software v2.3 and were exported for further calculations. 
For the detection of differentially expressed miR, delta Cqs of the corresponding miRNAs were 
calculated. Undetermined and very low expressed miRNAs (Cq >34.0 in both groups), were 
eliminated so that 309 miRNAs remained for further calculations. These miRNAs were ranked 
according to the Cq differences between both groups summarized in Table S1. Using a Cq difference 
of ≥1.5 corresponding a fold change of 2.82, 11 up- and 35 down-regulated miRNAs between non-
responders and responders were identified. We selected 11 miRs (miR-9-5p, miR-20b-5p, miR-203a-
3p, miR-204-5p, miR-223-3p, miR-342-3p, miR-483-5p, miR-489-3p, miR-500a-5p, miR-885-5p, and 
miR-1269a; miRBase 22 release, http://mirbase.org) with good PCR curves on the array cards for 
further validation. 
Supplementary Table S1. TaqMan MicroRNA Array data ranked according to the Cq-value 
differences between sunitinib non-responders and responders. The selected miRNAs according to the 
mentioned criteria used in the first validation step running on the LightCycler are marked in the last 
column. 
miR-Name 
AB-Assay ID 
Cq-Value 
Responder (R) 
Cq-Value 
Non-Responder 
Delta Cq  
R-(non-R) 
miR-Regulation 
(Non-R to R) 
One-Sided with 
Cq<33 
Assays Run 
on LC480 
hsa-miR-9-000583 31.26 26.79 4.5 up X 
hsa-miR-583-001623 36.91 32.79 4.1 up - 
hsa-miR-9#-002231 34.20 30.70 3.5 up - 
hsa-miR-483-5p-002338 32.60 30.49 2.1 up X 
hsa-miR-125a-3p-002199 35.10 33.17 1.9 up - 
hsa-miR-338-3p-002252 33.97 32.12 1.9 up - 
hsa-miR-483-3p-002339 31.17 29.32 1.9 up - 
hsa-miR-584-001624 33.55 31.70 1.8 up - 
hsa-miR-885-5p-002296 31.82 30.11 1.7 up X 
hsa-miR-1247-002893 30.43 28.83 1.6 up - 
hsa-miR-223-002295 24.66 23.12 1.5 up X 
hsa-miR-1300-002902 32.56 31.16 1.4 up  
hsa-miR-643-001594 33.44 32.24 1.2 up  
hsa-miR-1225-3P-002766 31.73 30.53 1.2 up  
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miR-Name 
AB-Assay ID 
Cq-Value 
Responder (R) 
Cq-Value 
Non-Responder 
Delta Cq  
R-(non-R) 
miR-Regulation 
(Non-R to R) 
One-Sided with 
Cq<33 
Assays Run 
on LC480 
hsa-miR-941-002183 33.43 32.26 1.2 up  
hsa-miR-431-001979 34.50 33.34 1.2 up  
hsa-miR-539-001286 34.52 33.38 1.1 up  
hsa-miR-20a#-002437 34.11 32.98 1.1 up  
hsa-miR-1248-002870 33.79 32.67 1.1 up  
hsa-miR-212-000515 33.99 32.89 1.1 up  
hsa-miR-143#-002146 31.32 30.24 1.1 up  
hsa-miR-638-001582 32.92 31.87 1.1 up  
hsa-miR-338-5P-002658 34.30 33.30 1.0 up  
hsa-miR-769-5p-001998 31.97 30.97 1.0 up  
hsa-miR-181a-2#-002317 32.52 31.53 1.0 up  
hsa-miR-572-001614 34.40 33.41 1.0 up  
hsa-miR-625-002431 34.12 33.21 0.9 up  
hsa-miR-1228#-002763 30.17 29.27 0.9 up  
hsa-miR-301b-002392 34.75 33.85 0.9 up  
hsa-miR-193b#-002366 34.38 33.50 0.9 up  
hsa-miR-199a-000498 34.18 33.40 0.8 up  
hsa-let-7e-002406 27.71 26.97 0.7 up  
hsa-miR-566-001533 30.80 30.06 0.7 up  
hsa-miR-142-3p-000464 26.18 25.49 0.7 up  
hsa-miR-424-000604 32.67 31.98 0.7 up  
hsa-miR-511-001111 34.56 33.88 0.7 up  
hsa-miR-200c-002300 30.22 29.55 0.7 up  
hsa-miR-190b-002263 34.09 33.43 0.7 up  
hsa-miR-636-002088 33.55 32.89 0.7 up  
hsa-miR-376a-000565 33.08 32.43 0.7 up  
hsa-miR-324-3p-002161 30.07 29.43 0.6 up  
hsa-miR-378-000567 34.02 33.43 0.6 up  
hsa-miR-376c-002122 30.22 29.65 0.6 up  
hsa-miR-144#-002148 32.52 31.98 0.5 up  
hsa-miR-29a#-002447 33.94 33.40 0.5 up  
hsa-miR-519e#-001166 33.47 32.95 0.5 up  
hsa-miR-199a-3p-002304 27.72 27.20 0.5 up  
hsa-miR-577-002675 34.10 33.59 0.5 up  
hsa-miR-98-000577 33.23 32.73 0.5 up  
hsa-miR-1275-002840 28.81 28.31 0.5 up  
hsa-miR-1255B-002801 33.33 32.83 0.5 up  
hsa-miR-328-000543 32.31 31.86 0.4 up  
hsa-miR-142-5p-002248 31.93 31.49 0.4 up  
hsa-miR-659-001514 33.05 32.62 0.4 up  
hsa-miR-192#-002272 32.70 32.27 0.4 up  
hsa-miR-1291-002838 32.75 32.33 0.4 up  
hsa-miR-335#-002185 32.63 32.23 0.4 up  
hsa-miR-661-001606 29.08 28.70 0.4 up  
hsa-miR-24-2#-002441 33.91 33.55 0.4 up  
hsa-miR-425-5p-001516 29.25 28.90 0.4 up  
hsa-miR-1285-002822 31.33 31.00 0.3 up  
hsa-miR-125b-000449 26.76 26.42 0.3 up  
hsa-miR-592-001546 31.09 30.76 0.3 up  
hsa-miR-502-3p-002083 34.24 33.92 0.3 up  
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miR-Name 
AB-Assay ID 
Cq-Value 
Responder (R) 
Cq-Value 
Non-Responder 
Delta Cq  
R-(non-R) 
miR-Regulation 
(Non-R to R) 
One-Sided with 
Cq<33 
Assays Run 
on LC480 
hsa-miR-15b#-002173 31.38 31.06 0.3 up  
hsa-miR-1270-002807 32.91 32.60 0.3 up  
hsa-miR-214-002306 28.86 28.55 0.3 up  
hsa-miR-411-001610 32.68 32.40 0.3 up  
hsa-miR-301-000528 31.35 31.09 0.3 up  
hsa-miR-155-002623 25.97 25.71 0.3 up  
hsa-miR-423-5p-002340 31.39 31.14 0.3 up  
hsa-miR-200b-002251 27.02 26.78 0.2 up  
hsa-let-7c-000379 31.65 31.42 0.2 up  
hsa-miR-150-000473 26.19 25.97 0.2 up  
hsa-miR-145#-002149 32.36 32.14 0.2 up  
hsa-miR-34a-000426 25.84 25.62 0.2 up  
hsa-miR-22#-002301 33.05 32.85 0.2 up  
hsa-miR-1227-002769 33.55 33.36 0.2 up  
hsa-miR-22-000398 25.98 25.79 0.2 up  
hsa-miR-24-000402 22.45 22.29 0.2 up  
hsa-miR-21-000397 22.47 22.32 0.2 up  
hsa-miR-370-002275 33.41 33.27 0.1 up  
hsa-let-7b-002619 26.59 26.45 0.1 up  
hsa-miR-136#-002100 34.04 33.91 0.1 up  
hsa-miR-33a#-002136 33.17 33.05 0.1 up  
hsa-miR-224-002099 30.23 30.10 0.1 up  
hsa-miR-19b-000396 23.34 23.24 0.1 up  
hsa-miR-106a-002169 24.32 24.23 0.1 up  
mean RNU44-001094 25.83 25.74 0.1 up  
hsa-let-7i#-002172 32.85 32.77 0.1 up  
hsa-miR-1253-002894 32.19 32.11 0.1 up  
hsa-miR-1274A-002883 22.41 22.33 0.1 up  
hsa-miR-346-000553 32.38 32.30 0.1 up  
hsa-miR-574-3p-002349 28.70 28.63 0.1 up  
hsa-miR-28-000411 29.29 29.25 0.0 =  
hsa-miR-628-5p-002433 32.01 31.96 0.0 =  
hsa-miR-15a-000389 28.66 28.62 0.0 =  
hsa-miR-218-000521 29.46 29.43 0.0 =  
hsa-miR-1183-002841 31.79 31.76 0.0 =  
hsa-miR-183#-002270 33.90 33.87 0.0 =  
hsa-miR-99b#-002196 32.88 32.86 0.0 =  
hsa-miR-31-002279 26.49 26.48 0.0 =  
hsa-miR-365-001020 30.64 30.62 0.0 =  
hsa-miR-151-3p-002254 26.63 26.63 0.0 =  
hsa-miR-505#-002087 32.85 32.85 0.0 =  
hsa-miR-939-002182 25.88 25.88 0.0 =  
hsa-miR-652-002352 30.33 30.33 0.0 =  
hsa-miR-19b-1#-002425 33.94 33.97 0.0 =  
hsa-miR-144-002676 31.77 31.80 0.0 =  
hsa-miR-135b-002261 28.27 28.30 0.0 =  
hsa-miR-214#-002293 32.17 32.20 0.0 =  
hsa-miR-1303-002792 33.13 33.17 0.0 =  
hsa-miR-494-002365 24.89 24.95 −0.1 down  
hsa-let-7g-002282 27.35 27.42 −0.1 down  
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miR-Name 
AB-Assay ID 
Cq-Value 
Responder (R) 
Cq-Value 
Non-Responder 
Delta Cq  
R-(non-R) 
miR-Regulation 
(Non-R to R) 
One-Sided with 
Cq<33 
Assays Run 
on LC480 
hsa-miR-185-002271 30.18 30.25 −0.1 down  
hsa-miR-34b-002102 32.85 32.92 −0.1 down  
hsa-miR-126#-000451 26.67 26.75 −0.1 down  
hsa-miR-1233-002768 28.24 28.32 −0.1 down  
hsa-miR-766-001986 30.38 30.46 −0.1 down  
hsa-miR-335-000546 32.31 32.40 −0.1 down  
hsa-miR-191-002299 24.85 24.94 −0.1 down  
hsa-miR-486-001278 30.14 30.24 −0.1 down  
hsa-miR-424#-002309 32.13 32.25 −0.1 down  
hsa-let-7g#-002118 33.42 33.57 −0.1 down  
hsa-miR-532-3p-002355 31.17 31.33 −0.2 down  
hsa-miR-200a-000502 27.46 27.63 −0.2 down  
hsa-miR-125a-5p-002198 27.72 27.88 −0.2 down  
hsa-miR-15b-000390 30.31 30.50 −0.2 down  
hsa-miR-99b-000436 28.75 28.94 −0.2 down  
hsa-miR-193a-3p-002250 31.55 31.75 −0.2 down  
hsa-miR-95-000433 31.39 31.59 −0.2 down  
hsa-miR-16-1#-002420 33.22 33.42 −0.2 down  
hsa-miR-10a-000387 28.59 28.79 −0.2 down  
hsa-miR-148a-000470 29.10 29.31 −0.2 down  
hsa-miR-145-002278 25.43 25.65 −0.2 down  
hsa-miR-17-002308 24.24 24.46 −0.2 down  
hsa-miR-509-5p-002235 32.51 32.73 −0.2 down  
mean U6 snRNA-001973 19.86 20.11 −0.3 down  
hsa-miR-122-002245 30.44 30.71 −0.3 down  
hsa-miR-487a-001279 31.71 31.98 −0.3 down  
hsa-miR-664-002897 28.36 28.63 −0.3 down  
hsa-miR-19a-000395 26.43 26.72 −0.3 down  
hsa-miR-146b-001097 25.72 26.03 −0.3 down  
hsa-miR-186#-002105 32.39 32.71 −0.3 down  
hsa-miR-130b-000456 31.07 31.39 −0.3 down  
hsa-miR-193a-5p-002281 30.14 30.47 −0.3 down  
hsa-miR-590-5p-001984 28.91 29.24 −0.3 down  
hsa-miR-497-001043 30.93 31.26 −0.3 down  
hsa-miR-28-3p-002446 27.45 27.79 −0.3 down  
hsa-let-7a-000377 30.01 30.35 −0.3 down  
hsa-miR-34a#-002316 31.97 32.31 −0.3 down  
hsa-miR-126-002228 21.54 21.89 −0.3 down  
hsa-miR-143-002249 25.94 26.30 −0.4 down  
hsa-miR-596-001550 27.16 27.52 −0.4 down  
hsa-miR-106b-000442 27.50 27.85 −0.4 down  
hsa-miR-331-000545 26.30 26.66 −0.4 down  
hsa-miR-140-3p-002234 28.79 29.16 −0.4 down  
hsa-miR-18b-002217 32.19 32.56 −0.4 down  
hsa-miR-1201-002781 32.62 32.99 −0.4 down  
hsa-miR-133a-002246 29.98 30.36 −0.4 down  
hsa-miR-152-000475 28.42 28.80 −0.4 down  
hsa-miR-103-000439 28.88 29.27 −0.4 down  
hsa-miR-454-002323 27.33 27.72 −0.4 down  
hsa-miR-141-000463 32.51 32.91 −0.4 down  
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miR-Name 
AB-Assay ID 
Cq-Value 
Responder (R) 
Cq-Value 
Non-Responder 
Delta Cq  
R-(non-R) 
miR-Regulation 
(Non-R to R) 
One-Sided with 
Cq<33 
Assays Run 
on LC480 
hsa-miR-202-002363 32.26 32.66 −0.4 down  
hsa-miR-20a-000580 25.35 25.75 −0.4 down  
hsa-let-7d-002283 29.94 30.35 −0.4 down  
hsa-miR-320-002277 26.40 26.80 −0.4 down  
hsa-miR-25-000403 30.51 30.93 −0.4 down  
hsa-miR-1290-002863 30.44 30.85 −0.4 down  
hsa-miR-196b-002215 27.55 27.97 −0.4 down  
hsa-miR-193b-002367 27.99 28.42 −0.4 down  
hsa-miR-16-000391 23.48 23.91 −0.4 down  
hsa-miR-571-001613 30.48 30.91 −0.4 down  
hsa-miR-339-3p-002184 29.81 30.26 −0.5 down  
hsa-miR-18a-002422 31.99 32.45 −0.5 down  
hsa-miR-1260-002896 25.63 26.10 −0.5 down  
hsa-miR-650-001603 29.40 29.87 −0.5 down  
hsa-miR-340-002258 31.94 32.42 −0.5 down  
hsa-miR-663B-002857 25.50 25.99 −0.5 down  
hsa-miR-215-000518 28.34 28.84 −0.5 down  
hsa-miR-337-5p-002156 33.29 33.79 −0.5 down  
hsa-miR-195-000494 25.52 26.03 −0.5 down  
hsa-miR-324-5p-000539 31.46 31.98 −0.5 down  
hsa-miR-501-001047 30.27 30.79 −0.5 down  
hsa-miR-1274B-002884 19.34 19.87 −0.5 down  
hsa-miR-15a#-002419 32.37 32.90 −0.5 down  
hsa-miR-99a-000435 26.41 26.96 −0.5 down  
hsa-miR-29a-002112 22.82 23.38 −0.6 down  
hsa-miR-31#-002113 29.58 30.14 −0.6 down  
hsa-miR-132-000457 28.52 29.09 −0.6 down  
hsa-miR-21#-002438 28.69 29.27 −0.6 down  
hsa-miR-598-001988 32.58 33.17 −0.6 down  
hsa-miR-101-002253 29.93 30.52 −0.6 down  
hsa-miR-361-000554 32.39 32.99 −0.6 down  
hsa-miR-649-001602 33.77 34.38 −0.6 down  
hsa-miR-708-002341 30.10 30.73 −0.6 down  
hsa-miR-130a-000454 29.21 29.84 −0.6 down  
hsa-miR-429-001024 29.63 30.27 −0.6 down  
hsa-miR-330-5p-002230 32.73 33.37 −0.6 down  
hsa-miR-296-000527 31.83 32.47 −0.6 down  
hsa-miR-10b-002218 27.52 28.16 −0.6 down  
hsa-miR-30b-000602 26.17 26.83 −0.7 down  
hsa-miR-1271-002779 31.37 32.03 −0.7 down  
hsa-miR-590-3P-002677 30.51 31.17 −0.7 down  
hsa-miR-139-5p-002289 30.29 30.96 −0.7 down  
hsa-miR-213-000516 30.95 31.62 −0.7 down  
hsa-miR-100-000437 26.41 27.08 −0.7 down  
hsa-miR-194-000493 26.33 27.01 −0.7 down  
hsa-miR-181a-000480 26.97 27.65 −0.7 down  
hsa-miR-29b-000413 29.34 30.02 −0.7 down  
hsa-miR-875-5p-002203 31.32 32.00 −0.7 down  
hsa-miR-192-000491 25.65 26.33 −0.7 down  
hsa-miR-484-001821 26.34 27.04 −0.7 down  
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miR-Name 
AB-Assay ID 
Cq-Value 
Responder (R) 
Cq-Value 
Non-Responder 
Delta Cq  
R-(non-R) 
miR-Regulation 
(Non-R to R) 
One-Sided with 
Cq<33 
Assays Run 
on LC480 
hsa-miR-26b-000407 26.92 27.63 −0.7 down  
hsa-miR-27a-000408 27.30 28.04 −0.7 down  
hsa-miR-92a-000431 29.57 30.31 −0.7 down  
hsa-miR-32-002109 32.34 33.09 −0.8 down  
hsa-miR-455-001280 28.46 29.22 −0.8 down  
hsa-miR-720-002895 19.54 20.30 −0.8 down  
hsa-miR-374-000563 28.42 29.22 −0.8 down  
hsa-miR-1180-002847 31.34 32.16 −0.8 down  
hsa-let-7f-000382 30.10 30.92 −0.8 down  
hsa-miR-10b#-002315 30.07 30.89 −0.8 down  
hsa-miR-30d-000420 25.70 26.54 −0.8 down  
hsa-miR-886-5p-002193 26.58 27.42 −0.8 down  
hsa-miR-138-002284 31.57 32.45 −0.9 down  
hsa-miR-455-3p-002244 32.18 33.08 −0.9 down  
hsa-miR-542-5p-002240 32.42 33.31 −0.9 down  
hsa-miR-151-5P-002642 29.93 30.83 −0.9 down  
hsa-miR-1825-002907 28.43 29.33 −0.9 down  
hsa-miR-30e-3p-000422 26.18 27.09 −0.9 down  
hsa-miR-1244-002791 31.87 32.78 −0.9 down  
hsa-miR-186-002285 27.44 28.37 −0.9 down  
hsa-miR-595-001987 33.54 34.48 −0.9 down  
hsa-miR-30c-000419 25.27 26.21 −0.9 down  
hsa-miR-361-3p-002116 31.38 32.35 −1.0 down  
hsa-miR-93#-002139 30.20 31.17 −1.0 down  
hsa-miR-30d#-002305 31.10 32.08 −1.0 down  
hsa-miR-362-3p-002117 32.35 33.33 −1.0 down  
hsa-miR-210-000512 24.46 25.44 −1.0 down  
hsa-miR-339-5p-002257 30.09 31.08 −1.0 down  
hsa-miR-27b-000409 28.96 29.95 −1.0 down  
hsa-miR-886-3p-002194 25.46 26.48 −1.0 down  
hsa-miR-550-001544 31.18 32.21 −1.0 down  
hsa-miR-628-3p-002434 33.81 34.84 −1.0 down  
hsa-miR-133b-002247 33.11 34.14 −1.0 down  
hsa-miR-149-002255 30.43 31.48 −1.0 down  
hsa-miR-639-001583 31.34 32.39 −1.0 down  
hsa-miR-567-001534 33.92 34.97 −1.0 down  
hsa-miR-657-001512 33.01 34.08 −1.1 down  
hsa-miR-660-001515 26.90 27.98 −1.1 down  
hsa-miR-181c-000482 31.79 32.88 −1.1 down  
hsa-miR-135a-000460 30.25 31.36 −1.1 down  
hsa-miR-331-5p-002233 32.59 33.72 −1.1 down  
hsa-miR-532-001518 28.71 29.85 −1.1 down  
hsa-miR-378-002243 27.07 28.22 −1.1 down  
hsa-miR-30a-5p-000417 24.24 25.40 −1.2 down  
hsa-miR-106b#-002380 32.85 34.02 −1.2 down  
hsa-miR-362-001273 31.11 32.33 −1.2 down  
hsa-miR-148b#-002160 32.97 34.21 −1.2 down  
hsa-miR-26a-000405 25.17 26.43 −1.3 down  
hsa-miR-27b#-002174 32.96 34.25 −1.3 down  
hsa-miR-29c-000587 27.12 28.41 −1.3 down  
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miR-Name 
AB-Assay ID 
Cq-Value 
Responder (R) 
Cq-Value 
Non-Responder 
Delta Cq  
R-(non-R) 
miR-Regulation 
(Non-R to R) 
One-Sided with 
Cq<33 
Assays Run 
on LC480 
mean RNU48-001006 25.50 26.84 −1.3 down  
hsa-miR-30a-3p-000416 25.15 26.54 −1.4 down  
hsa-miR-148b-000471 31.77 33.17 −1.4 down  
hsa-miR-92b#-002343 32.80 34.20 −1.4 down  
hsa-miR-345-002186 29.36 30.77 −1.4 down  
hsa-miR-146a-000468 25.71 27.12 −1.4 down  
hsa-miR-23a-000399 31.07 32.48 −1.4 down  
hsa-miR-23b-000400 30.95 32.37 −1.4 down  
hsa-miR-127-000452 31.82 33.25 −1.4 down  
hsa-miR-221-000524 28.54 29.97 −1.4 down  
hsa-miR-629-001562 33.70 35.16 −1.5 down - 
hsa-miR-1208-002880 32.31 33.78 −1.5 down - 
hsa-miR-625#-002432 30.58 32.04 −1.5 down - 
hsa-miR-744-002324 29.83 31.29 −1.5 down - 
hsa-miR-450a-002303 32.82 34.30 −1.5 down - 
hsa-miR-222-002276 25.20 26.69 −1.5 down - 
hsa-miR-99a#-002141 31.63 33.17 −1.5 down - 
hsa-miR-422a-002297 33.57 35.17 −1.6 down - 
hsa-miR-197-000497 29.48 31.10 −1.6 down - 
hsa-miR-26a-1#-002443 33.83 35.45 −1.6 down - 
hsa-miR-452-002329 29.90 31.58 −1.7 down - 
hsa-miR-622-001553 31.48 33.22 −1.7 down - 
hsa-miR-520D-3P-002743 33.79 35.54 −1.8 down - 
hsa-miR-597-001551 33.53 35.29 −1.8 down - 
hsa-miR-17#-002421 32.89 34.66 −1.8 down - 
hsa-miR-342-3p-002260 26.55 28.38 −1.8 down X 
hsa-miR-190-000489 32.37 34.23 −1.9 down - 
hsa-miR-675-002005 31.31 33.19 −1.9 down - 
hsa-miR-222#-002097 31.48 33.39 −1.9 down - 
hsa-miR-204-000508 26.24 28.16 −1.9 down X 
hsa-miR-500-002428 31.20 33.15 −1.9 down X 
hsa-miR-580-001621 33.09 35.04 −2.0 down - 
hsa-miR-486-3p-002093 31.35 33.33 −2.0 down - 
hsa-miR-200a#-001011 32.88 34.90 −2.0 down - 
hsa-miR-548d-5p-002237 32.92 35.07 −2.1 down - 
hsa-miR-1305-002867 32.79 34.96 −2.2 down - 
hsa-miR-296-3p-002101 33.66 35.86 −2.2 down - 
hsa-miR-545-002267 33.08 35.44 −2.4 down - 
hsa-miR-564-001531 32.35 34.81 −2.5 down - 
hsa-miR-20b-001014 28.44 30.93 −2.5 down X 
hsa-miR-203-000507 31.14 33.78 −2.6 down X 
hsa-miR-181c#-002333 31.43 34.14 −2.7 down - 
hsa-miR-1269-002789 31.45 34.25 −2.8 down X 
hsa-miR-644-001596 33.26 36.19 −2.9 down - 
hsa-miR-489-002358 27.08 30.58 −3.5 down X 
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Information S2: RT-qPCR and droplet digital PCR methodologies. 
General comments regarding the PCR guidelines and RNA quality data. 
RT-qPCR measurements were performed according to the recommendations of the MIQE 
guidelines [1]. Corresponding comments are listed in the following checklist (Supplementary Table 
S2 and the Section "Pre-testing step: RT-qPCR with the LightCycler 480"). This also applies for the 
droplet digital PCR measurements according to the digital MIQE guidelines [2] shown in 
Supplementary Table S3 with corresponding comments and experimental details in the section 
"Validation step: Droplet digital PCR using the QX200 digital PCR instrument". No template controls 
(NTC) and no reverse-transcription controls (NRTC or no enzyme controls = NEC) were always 
performed and showed negative results. 
RNA was extracted from formalin-fixed, paraffin-embedded (FFPE) tissue samples (mean: 15.5 
± 4.6 mg). The median RNA yield from one mg of FFPE tissue sample amounted to 961 ng (95% CI, 
529–1746 ng) for non-responders and 1217 ng (95% CI, 691–1859) for responders and did not differ 
between the two cohorts (Mann–Whitney U-test, P = 0.499). The purity of isolated RNA samples 
defined by the 260 nm to 280 nm absorbance ratio (median, 95% CI 1.89, 1.84–1.92 for non-responders 
and 1.90, 1.85–1.93 for responders) also did not differ between the study groups (Mann–Whitney 
U-test, P = 0.669) and fulfilled the purity criterion for down-stream measurements. RNA integrity 
was not determined since our previous studies proved that miRNA stability is not decreased in total 
RNA samples with low RNA integrity [3]. 
Table S2. MIQE checklist according to Bustin et al. [1]. 
Item to Check Importance Checklist Where?; Comment   
Experimental Design        
Definition of experimental and control  
groups 
E Yes Main text: Materials and Methods; Table I; Figure 1: 
Flow diagram  
 
Number within each group E Yes Main text: Materials and Methods; Table I; Figure 1: 
Flow diagram 
 
Assay carried out by core lab or 
investigator's lab? 
D Yes Investigator's lab  
Acknowledgement of authors' 
contributions  
D No    
SAMPLE        
Description E Yes Main text: Materials and Methods, Patients and 
samples; RNA extraction...; Results: Study design, 
patients and sample characteristics; Supplementary 
Information S2, General comments  
 
 Volume/mass of sample processed D Yes Main text: Materials and Methods, Patients and 
samples; RNA extraction...; Results: Study design, 
patients and sample characteristics; Supplementary 
Information S2, General comments 
 
 Microdissection or macrodissection E Yes Main text: Materials and Methods, Patients and 
samples; RNA extraction...; Results: Study design, 
patients and sample characteristics; Supplementary 
Information S2, General comments 
 
Processing procedure E Yes Main text: Materials and Methods, Patients and 
samples  
 
 If frozen - how and how quickly? E Not applicable FFPE material; see below  
 If fixed - with what, how quickly? E Yes Tissue fixation immediately after nephrectomy in 
neutral-buffered formaldehyde solution for tissue 
fixation 
 
Sample storage conditions and duration 
(esp. for FFPE samples) 
E Yes Main text: Materials and Methods: Patients and 
samples 
 
Nucleic Acid Extraction        
Procedure and/or instrumentation E Yes Main text: Materials and Methods, RNA extraction  
 Name of kit and details of any 
modifications 
E Yes Main text: Materials and Methods, RNA extraction: 
miRNeasy FFPE Kit (Qiagen, Cat. No. 217504) 
 
 Source of additional reagents used  D No   
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Details of DNase or RNAse treatment E Yes Main text: Materials and Methods, RNA extraction: 
on-column DNase digestion 
 
Contamination assessment (DNA or 
RNA) 
E Yes Main text: Materials and Methods, RNA extraction: 
on-column DNase digestion; Supplementary 
Information S2: General comments: DNA 
contamination was excluded by reaction without 
reverse transcription in pilot experiments; in 
addition, this principle of miRNAs is not affected by 
genomic DNA contamination according to the 
manufacturer 
Nucleic acid quantification  E Yes Main text: Materials and Methods; RNA extraction: 
NanoDrop ND-1000; spectrophotometry 
 
 Instrument and method E Yes Main text: Materials and Methods; RNA extraction: 
NanoDrop ND-1000; spectrophotometry 
 
 Purity (A260/A280)  D Yes Main text: Results, Study design and characteristics 
of patients and samples; Supplementary Information 
S2, General comments 
 
 Yield D Yes Main text: Results, Study design and characteristics 
of patients and samples; Supplementary Information 
S2, General comments 
 
RNA integrity method/instrument E Yes Main text: Results, Study design and characteristics 
of patients and samples; Supplementary Information 
S2: General comments 
 
 RIN/RQI or Cq of 3' and 5' transcripts  E Yes Supplementary Information S2: General comments  
 Electrophoresis traces D No   
Inhibition testing (Cq dilutions, spike or 
other)  
E Yes Supplementary Information S2 with Supplementary 
Figure. S1 with standard curves and their 
characteristics 
 
Storage conditions (Nucleic acid): 
temperature, concentration, duration, 
buffer) 
E Yes Main text: RNA extraction...: storage in nuclease-free 
water in two aliquots after isolation at −80 °C up to 
cDNA synthesis 
 
Reverse Transcription        
Complete reaction conditions E Yes Supplementary Information S2: cDNA synthesis and 
RT-PCR methodology 
 
 Amount of RNA and reaction volume E Yes Supplementary Information S2: cDNA synthesis   
 Priming oligonucleotide (if using 
GSP) and concentration 
E Yes Supplementary Information S2: cDNA synthesis, 
Supplementary Table S4 
 
 Reverse transcriptase and 
concentration 
E Yes Supplementary Information S2: cDNA synthesis   
 Temperature and time E Yes Supplementary Information S2: cDNA synthesis a  
 Manufacturer of reagents and 
catalogue numbers 
D Yes Main text: Materials and Methods, ...miRNA 
quantification and Supplementary Information S2: 
cDNA synthesis  
 
Cqs with and without RT D Yes Supplementary Information S2: RT-PCR 
methodology, General comments; see also comment 
on DNase treatment concerning miRNAs 
 
Storage conditions of cDNA D Yes Supplementary Information S2: cDNA synthesis; 
storage at −20 °C 
 
qPCR Target Information        
Gene symbols E Yes Main text: Materials and Methods, ...miRNA 
quantification and Supplementary Information S2: 
Supplementary Table S4 
 
If multiplex, efficiency and LOD of each 
assay. 
E Not applicable   
Sequence accession number E Yes Main text: Materials and Methods, ...miRNA 
quantification and Supplementary Information S2: 
Supplementary Table S4 
 
Location of amplicon D Yes Supplementary Information S2: Supplementary 
Table S4; controlled by the manufacturer of the 
miRNA assays (Thermo Fisher, Applied Biosystems) 
 
 Amplicon length E Yes Controlled by the manufacturer of the miRNA 
assays (Thermo Fisher, Applied Biosystems); own 
electrophoretic results showed 60–80 bp 
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 In silico specificity screen (BLAST, 
etc.) 
E Yes Controlled by the manufacturer of the miRNA 
assays (Thermo Fisher, Applied Biosystems) 
 
 Pseudogenes, retropseudogenes or 
other homologs? 
D Yes Controlled by the manufacturer of the miRNA 
assays (Thermo Fisher, Applied Biosystems) 
 
 Sequence alignment D Yes Controlled by the manufacturer of the miRNA 
assays (Thermo Fisher, Applied Biosystems) 
 
 Secondary structure analysis of 
amplicon 
D Yes Controlled by the manufacturer of the miRNA 
assays (Thermo Fisher, Applied Biosystems) 
 
Location of each primer by exon or 
intron (if applicable) 
E Yes Controlled by the manufacturer of the miRNA 
assays (Thermo Fisher, Applied Biosystems) 
 
 What splice variants are targeted? E Yes Controlled by the manufacturer of the miRNA 
assays (Thermo Fisher, Applied Biosystems) 
 
qPCR Oligonucleotides        
Primer sequences E Yes Supplementary Information S2, quantitative real-
time PCR: use of commercial kits (Thermo Fisher, 
Applied Biosystems); Supplementary Table S4  
 
RTPrimerDB Identification Number  D No  
Probe sequences D Yes Supplementary Information S2, quantitative real-
time PCR: use of commercial kits (Thermo Fisher, 
Applied Biosystems). Manufacturer does not 
provide this information 
Location and identity of any 
modifications 
E Yes Supplementary Information S2, quantitative real-
time PCR: use of commercial kits (Thermo Fisher, 
Applied Biosystems), Supplementary Table S4 
 
Manufacturer of oligonucleotides D Yes Supplementary Information S2, quantitative real-
time PCR: use of commercial kits (Thermo Fisher, 
Applied Biosystems). Manufacturer does not 
provide this information 
 
Purification method D Not applicable Supplementary Information S2, quantitative real-
time PCR: use of commercial kits (Thermo Fisher, 
Applied Biosystems). Manufacturer does not 
provide this information 
 
qPCR Protocol        
Complete reaction conditions E Yes Main text: Materials and Methods:.....miRNA 
quantification and Supplementary Information S2, 
using commercial tests, Supplementary Table S4 and 
quantitative real-time PCR 
 
 Reaction volume and amount of 
cDNA/DNA 
E Yes Main text: Materials and Methods, ....miRNA 
quantification; Supplementary Information S2, 
quantitative real-time PCR 
 
 Primer, (probe), Mg++ and dNTP 
concentrations 
E Yes Main text: Materials and Methods, ....miRNA 
quantification; Supplementary Information S2, 
quantitative real-time PCR; details not provided by 
the manufacturer 
 
 Polymerase identity and 
concentration  
E Yes Main text: Materials and Methods, ....miRNA 
quantification; Supplementary Information S2 and 
Supplementary Table S4, quantitative real-time PCR; 
details not provided by the manufacturer 
 
 Buffer/kit identity and manufacturer  E Yes Main text: Materials and Methods, ....miRNA 
quantification; Supplementary Information S2 and 
Supplementary Table S4, quantitative real-time PCR; 
details not provided by the manufacturer 
 
 Exact chemical constitution of the 
buffer 
D No Use of commercial tests, Supplementary Table S4; 
details are not provided by the manufacturer 
 
 Additives (SYBR Green I, DMSO, etc.) E Not applicable   
Manufacturer of plates/tubes and 
catalogue number 
D Yes Main text: Materials and Methods, ..miRNA 
quantification; Supplementary Information S2: 
quantitative real-time PCR white 96-well plates 
(Roche) 
 
Complete thermocycling parameters E Yes Supplementary Information S2: quantitative real-
time PCR 
 
Reaction setup (manual/robotic) D Yes Manual setup   
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Manufacturer of qPCR instrument E Yes Main text: Materials and Methods, ...miRNA 
quantification; Supplementary Information S2: 
quantitative real-time PCR (LightCycler, Roche)  
 
qPCR Validation        
Evidence of optimisation (from 
gradients)  
D No Main text: Materials and Methods, ...miRNA 
quantification; Supplementary Information S2,: 
quantitative real-time PCR: Supplementary Table S4, 
use of commercial kits (Thermo Fisher, Applied 
Biosystems) 
 
Specificity (gel, sequence,  melt, or 
digest) 
E Yes Controlled by the manufacturer of the miRNA 
assays (Thermo Fisher, Applied Biosystems) 
 
For SYBR Green I, Cq of the NTC E Not applicable   
Standard curves with slope and y-
intercept 
E Yes Supplementary Information S2: Performance data of 
qPCR with Supplementary Figure S1 and legends 
 
 PCR efficiency calculated from slope E Yes Supplementary Information S2: Performance data of 
qPCR with Supplementary Figure S1 and legends 
 
 Confidence interval for PCR 
efficiency or standard error 
D Yes Supplementary Information S2: Performance data of 
qPCR with Supplementary Figure S1 and legends 
 
 r2 of standard curve E No Not provided by the LC480 software  
Linear dynamic range E Yes Supplementary Information S2: quantitative real-
time PCR  
 
 Cq variation at lower limit E Yes Supplementary Information S2: Performance data 
with Supplementary Table S5 
 Confidence intervals throughout 
range 
D No    
Evidence for limit of detection  E No Dynamic range from 11 to 35 Cqs, but all measured 
miRNAs had Cqs <34 
 
If multiplex, efficiency and LOD of each 
assay. 
E Not applicable   
Data Analysis        
qPCR analysis program (source, version) E Yes Main text: Materials and Methods, ..miRNA 
quantification; Supplementary Information S2: 
quantitative real-time PCR with LightCycler 
software, release 1.5.0 using the “second derivative 
maximum” method 
 
 Cq method determination E Yes  
 Outlier identification and disposition E Not applicable    
Results of NTCs  E Yes Supplementary Information S2: General comments  
Justification of number and choice of 
reference genes 
E Yes  Main text: Materials and Methods, ...miRNA 
quantification; in the pretesting approach using 
LightCycler, miR-103 was initially envisaged as 
normalizer, but the validation approach was 
continued using droplet digital PCR without the 
necessity of normalizers 
 
Description of normalisation method E Not applicable See previous comment  
Number and concordance of biological 
replicates 
D Yes Example of concordance between matched samples 
measured on the array platform and LightCycler: 
Supplementary Figure S2  
 
Number and stage (RT or qPCR) of 
technical replicates 
E Yes Supplementary Information S2: ...miRNA 
quantification using triplicates. Example of 
concordance between matched samples measured 
on the array platform and LightCycler: 
Supplementary Figure S2 
 
Repeatability (intra-assay variation) E Yes See reproducibility data as preferred performance 
criterion 
 
Reproducibility (inter-assay variation, 
%CV) 
D Yes  Supplementary Information S2: Performance data, 
see Supplementary Table S5 
 
Power analysis D Yes Main text: Results: Study design, patients and 
sample characteristics 
 
Statistical methods for result significance E Yes Main text: Materials and Methods, Data analysis and 
statistics 
 
Software (source, version) E Yes Main text: Materials and Methods: Data analysis and 
statistics 
 
Cq or raw data submission using RDML D No   
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Table S3. Digital MIQE checklist according to Huggett et al. [2]. 
Item to Check Importance Checklist Where?; Comment 
Experimental Design       
Definition of experimental and 
control groups 
E Yes 
Main text: Materials and Methods; Table I; Figure 1: 
Flow diagram  
Number within each group E Yes 
Main text: Materials and Methods; Table I; Figure 1: 
Flow diagram 
Assay carried out by core lab or 
investigator's lab? 
D Yes Investigator's lab 
Power analysis D Yes 
Main text: Results: Study design, patients and sample 
characteristics  
Sample     
Description E Yes 
Main text: Materials and Methods, Patients and 
samples; RNA extraction...; Results: Study design, 
patients and sample characteristics; Supplementary 
Information S2, General comments  
 Volume/mass of sample 
processed 
D Yes 
Main text: Materials and Methods, Patients and 
samples; RNA extraction...; Results: Study design, 
patients and sample characteristics; Supplementary 
Information S2, General comments 
 Microdissection or 
macrodissection 
E Yes 
Main text: Materials and Methods, Patients and 
samples; RNA extraction...; Results: Study design, 
patients and sample characteristics; Supplementary 
Information S2, General comments 
Processing procedure E Yes 
Main text: Materials and Methods, Patients and 
samples  
 If frozen - how and how quickly? E 
Not 
applicable 
FFPE material; see below 
 If fixed - with what, how quickly? E Yes 
Tissue fixation immediately after nephrectomy in 
neutral-buffered formaldehyde solution for tissue 
fixation 
Sample storage conditions and 
duration (especially for FFPE 
samples) 
E Yes 
Main text: Materials and Methods: Patients and 
samples  
Nucleic Acid Extraction     
Manufacturer of reagents used and 
catalogue number 
D Yes 
Main text: Materials and Methods, RNA extraction: 
miRNeasy FFPE Kit (Qiagen, Cat. No. 217504) 
Quantification -instrument/method  E Yes 
Main text: Materials and Methods; RNA extraction: 
NanoDrop ND-1000; spectrophotometry 
DNA or RNA quantification E Yes RNA 
Quality/Integrity, 
method/instrument, e.g. RNA 
integrity 
E Yes 
Supplementary Information S2: General comments: 
A260/A280 ratio; Main text, Results: Study design, 
patients and sample characteristics 
Template structural information E Yes 
See above; RNA extraction using miRNeasy FFPE Kit 
Qiagen 
Template modification (digestion, 
sonication, preamplification, etc.) 
E Yes 
Main text: Materials and Methods, RNA extraction. : 
deparaffinization, tissue lysis (TissueLyser, Qiagen), 
proteinase K digestion 
Template treatment E Yes 
Main text: Materials and Methods, RNA extraction. 
:deparaffinization, tissue lysis (TissueLyser, Qiagen), 
proteinase K digestion 
Inhibition dilutions or spike E Yes 
See Supplementary Table S2 and standard curves in 
Supplementary Figure S1; cDNA was diluted 
according to dilution schemes indicated in 
Supplementary Table S6   
DNA contamination assessment of 
RNA samples 
E Yes 
Main text: Materials and Methods, RNA extraction: 
on-column DNase digestion; Supplementary 
Information S2: General comments: DNA 
contamination was excluded by reaction without 
reverse transcription in pilot experiments; in 
addition, this principle of miRNAs is not affected by 
genomic DNA contamination according to the 
manufacturer 
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Details of DNase treatment where 
performed 
E Yes See previous comment: on-column DNase treatment  
Storage conditions (Nucleic acid): 
temperature, concentration, 
duration, buffer) 
E Yes 
Main text: RNA extraction...: storage in nucleases-
free water in two aliquots after isolation at −80 °C up 
to cDNA synthesis 
Reverse Transcription (if necessary)     
cDNA priming method and 
concentration 
E Yes 
Main text: Materials and Methods, ...miRNA 
quantification; Supplementary Information S2, cDNA 
synthesis-specific stem-loop RT primer, see 
Supplementary Table S4 
One- or two-step protocol E Yes Main text: Materials and Methods, two-step protocol 
Amount of RNA used per reaction E Yes Supplementary Information S2: cDNA synthesis 
Detailed reaction components and 
conditions 
E Yes Supplementary Information S2: cDNA synthesis 
RT efficiency D No  
Estimated copies measured with and 
without addition of RT 
D Yes Supplementary Information S2, General comments 
Manufacturer of reagents and 
catalogue numbers 
D Yes 
Main text: Materials and Methods, ...miRNA 
quantification and Supplementary Information S2: 
cDNA synthesis 
Reaction volume D  Supplementary Information S2: cDNA synthesis 
Storage conditions of cDNA D  
Supplementary Information S2: cDNA synthesis; 
storage at −20 °C 
dPCR Target Information     
Sequence accession number E Yes 
Main text: Materials and Methods, ...miRNA 
quantification and Supplementary Information S2: 
Supplementary Table S4 
Location of amplicon D Yes 
Supplementary Information S2: Supplementary Table 
S4; controlled by the manufacturer of the miRNA 
assays (Thermo Fisher, Applied Biosystems) 
Amplicon length E Yes 
Controlled by the manufacturer of the miRNA assays 
(Thermo Fisher, Applied Biosystems); own 
electrophoretic results showed 60-80 bp 
In silico specificity screen (BLAST, 
etc) 
E Yes 
Controlled by the manufacturer of the miRNA assays 
(Thermo Fisher, Applied Biosystems) 
Pseudogenes, retropseudogenes or 
other homologs? 
D Yes 
Controlled by the manufacturer of the miRNA assays 
(Thermo Fisher, Applied Biosystems) 
Sequence alignment D Yes 
Controlled by the manufacturer of the miRNA assays 
(Thermo Fisher, Applied Biosystems) 
Secondary structure analysis of 
amplicon and GC content 
D Yes 
Controlled by the manufacturer of the miRNA assays 
(Thermo Fisher, Applied Biosystems) 
Location of each primer by exon or 
intron (if applicable) 
E Yes 
Controlled by the manufacturer of the miRNA assays 
(Thermo Fisher, Applied Biosystems) 
What splice variants are targeted? E Yes 
Controlled by the manufacturer of the miRNA assays 
(Thermo Fisher, Applied Biosystems) 
dPCR Oligonucleotides     
Primer sequences E Yes 
Supplementary Information S2, Supplementary Table 
S4: use of commercial kits (Thermo Fisher, Applied 
Biosystems) 
RTPrimerDB Identification Number  D No  
Probe sequences D Yes 
Main text: Materials and Methods...miRNA 
quantification: use of commercial kits (Thermo 
Fisher, Applied Biosystems). Manufacturer does not 
provide this information 
Location and identity of any 
modifications 
E Yes 
Main text: Materials and Methods...miRNA 
quantification: use of commercial kits (Thermo 
Fisher, Applied Biosystems), Supplementary Table 
S4 
Manufacturer of oligonucleotides D Yes 
Main text: Materials and Methods...miRNA 
quantification: use of commercial kits (Thermo 
Fisher, Applied Biosystems). Manufacturer does not 
provide this information 
Purification method D 
Not 
applicable 
Main text: Materials and Methods...miRNA 
quantification: use of commercial kits (Thermo 
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Fisher, Applied Biosystems). Manufacturer does not 
provide this information 
dPCR Protocol    
Complete reaction conditions E Yesq 
Main text: Materials and Methods, miRNA 
quantification; Supplementary Information S2, 
Supplementary Table S6 
 Reaction volume and amount of 
cDNA/DNA 
E Yes 
Main text: Materials and Methods, miRNA 
quantification; Supplementary Information S2, 
Supplementary Table S6 
 Primer, (probe), Mg++ and dNTP 
concentrations 
E Yes 
Main text: Materials and Methods, miRNA 
quantification; Supplementary Information S2, 
Supplementary Tables S4 and 6; not all details are 
provided by the manufacturer 
 Polymerase identity and 
concentration  
E Yes 
Main text: Materials and Methods, miRNA 
quantification; Supplementary Information S2, 
Supplementary Tables S4 and 6; not all details are 
provided by the manufacturer 
 Buffer/kit identity and 
manufacturer  
E Yes 
Main text: Materials and Methods, miRNA 
quantification; Supplementary Information S2, 
Supplementary Tables S4 and 6 
 Exact chemical constitution of the 
buffer 
D No 
Main text: Materials and Methods, miRNA 
quantification; Supplementary Information S2, 
Supplementary Tables S4 and 6, but not all details 
are provided by the manufacturer 
 Additives (SYBR Green I, DMSO, 
etc.) 
E 
Not 
applicable  
 
Plates/tubes catalogue number and 
manufacturer 
D Yes 
Main text: Materials and Methods, miRNA 
quantification; Supplementary Information S2, 
Supplementary Table S6 
Complete thermocycling parameters E Yes 
Main text: Materials and Methods, miRNA 
quantification; Supplementary Information S2, 
Supplementary Table S6 
Reaction setup (manual/robotic) D Yes Manual setup 
Gravimetric or volumetric dilutions 
(manual/robotic) 
D Yes 
Supplementary Information S2, Supplementary Table 
S6 
Total PCR volume prepared D Yes 
Main text: Materials and Methods, miRNA 
quantification; Supplementary Information S2, 
Supplementary Table S6 
Partition number E Yes 
Supplementary Information S2, Supplementary 
Tables S6–8, Supplementary Figure S3 
Individual partition volume E Yes Provided by the manufacturer: 1 nL 
Total volume of the partitions 
measured (effective reaction size) 
E Yes 
Supplementary Information S2, Supplementary 
Tables S6–8, Supplementary Figure S3 
Partition volume variance/SD D Yes 
Supplementary Information S2, Supplementary 
Tables S6–8, Supplementary Figure S3 
Comprehensive details and 
appropriate use of controls 
E Yes 
Supplementary Information S2, Supplementary Table 
S8 
Manufacturer of dPCR instrument E Yes 
Main text: Materials and Methods, miRNA 
quantification; Supplementary Table S6 (QX200 
ddPCR System from BIO-RAD) 
dPCR Validation     
Optimisation data for the assay D Yes 
Only partly optimized by optimizing the annealing 
temperature using thermal gradients since the 
original tests provided reliable results as shown in 
control experiments (Supplementary Table S8) 
Specificity (when measuring rare 
mutations, pathogen sequences, etc.) 
E 
Not 
applicable 
 
Limit of detection of calibration 
control 
D 
Not 
applicable 
 
If multiplexing, comparison with 
singleplex assays 
E 
Not 
applicable 
 
DATA Analysis     
Mean copies per partition (λ or 
equivalent) 
E  
Supplementary Information S2, Supplementary Table 
S7 
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dPCR analysis program (source, 
version) 
E Yes 
Main text: Materials and Methods, miRNA 
quantification; Supplementary Information S2, 
Supplementary Table S6: QuantaSoft Software Vs. 
1.7.4.0917 from BIO-RAD 
Outlier identification and 
disposition 
E Yes 
Supplementary Information S2, Supplementary Table 
S3: legend  
Results of NTCs  E Yes Supplementary Information S2, General comments 
Examples of positive(s) and negative 
experimental results as 
supplemental data 
E No  
Where appropriate, justification of 
number and choice of reference 
genes 
E No 
Main text: Materials and Methods, ...miRNA 
quantification; in the pretesting approach using 
LightCycler, miR-103 was initially envisaged as 
normalizer, but the validation approach was 
continued using droplet digital PCR without the 
necessity of normalizers 
Where appropriate, description of 
normalization method 
E No  
Number and concordance of 
biological replicates 
D Yes 
Example of concordance between matched samples 
measured on the array platform and on LightCycler 
in the pretesting step: Supplementary Figure S2. 
Independent biological replicates as shown in the 
study were preferred  
Number and stage (RT or qPCR) of 
technical replicates 
E Yes 
Duplicate qPCR measurements, see Supplementary 
Table S8, Part A  
Repeatability (intra-assay variation) E Yes 
Supplementary Information S2, Supplementary Table 
S8, Part A 
Reproducibility (inter-assay/user/lab 
etc variation) 
D Yes 
Supplementary Information S2, Supplementary Table 
S8, Part B 
Experimental variance or CI d E Yes 
Supplementary Information S2, Supplementary Table 
S8 
Statistical methods for analysis E Yes 
Main text: Materials and Methods, Data analysis and 
statistics 
Data submission using RDML (Real-
time PCR Data Markup Language) 
D No  
In the following sections, the quantification of the selected differentially expressed miRs and 
analytical performance data for all the measurements are compiled. 
Pre-testing step: RT-qPCR analyses with the LightCycler 480. 
The 11 selected differentially expressed miRNAs using the card array technique were measured 
in the pretesting step using TaqMan microRNA Reverse-Transcription Kits (Supplementary Table 
S4) with details given in the following and based on our previous publications [3–6]. 
Table S4. TaqMan MicroRNA assays used for RT-qPCR and droplet digital PCR: nomenclature and 
sequences of the miRNAs. Assay names and assay IDs are taken from the nomenclature of the 
supplier Thermo Fisher. The miRBase accession no., miRBase ID, and the target sequences were taken 
from the miRBase database release 22 (Sanger Institute, Manchester, UK; http://www.mirbase.org). 
miRBase ID 
Release Version 
22 
miRBase 
Accession 
No. 
AB Assay 
Name 
AB 
Assay 
ID 
Sequence 
Chromosome 
Location/ 
Coordinates on 
Build GRCh38 
hsa-miR-9-5p MIMAT0000441 hsa-miR-9 000583 UCUUUGGUUAUCUAGCUGUAUGA 
Chr. 1: 156420341 
- 156420429 [−] 
hsa-miR-20b-5p MIMAT0001413 hsa-miR-20b 001014 CAAAGUGCUCAUAGUGCAGGUAG 
Chr.X: 134169809 
- 134169877 [−] 
hsa-miR-203a-3p MIMAT0000264 hsa-miR-203 000507 GUGAAAUGUUUAGGACCACUAG 
Chr.14: 104117405 
- 104117514 [+] 
hsa-miR-204-5p MIMAT0000265 hsa-miR-204 000508 UUCCCUUUGUCAUCCUAUGCCU 
Chr. 9: 70809975 - 
70810084 [−] 
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&Hsa-miR-103a-3p was initially envisaged to be used as normalizer for the RT-qPCR analyses. 
cDNA synthesis. 
Total RNA was transcribed in cDNA with the TaqMan MicroRNA Reverse-Transcription Kit 
(Thermo Fisher, Applied Biosystems, Cat. No. 4366596) and miRNA specific stem-loop RT primers 
(Thermo Fisher, Applied Biosystems, Part No: 4427975). A final reaction mix of 10 µL included: 0.1 
µL of dNTPs (100 mM total), 0.67 µL of MultiScribe RT (50 U/µL MuLV-RT), 1 µL of 10x RT-Buffer, 
0.13 µL of RNase inhibitor (20 U/µL), 1 µL of miR-specific 5x RT primer, 1 µL of RNA (6.67 ng), and 
6.1 µL of nuclease-free water. The transcription and detection of gDNA was separately controlled by 
full reaction mix without MultiScribe reverse transcriptase addition for each individual miRNA. The 
transcription was performed on a thermal block cycler with heated lid (Biometra, Göttingen, 
Germany) using the following conditions: 30 min at 16 °C (annealing), 30 min at 42 °C (transcription), 
5 min at 85 °C (enzyme inactivation), final cooling to 4 °C and storage of cDNA at −20 °C until 
analysis. 
Quantitative real-time PCR. 
In the pretesting step, the individual TaqMan miRNA assays were performed on the LightCycler 
480 Instrument (Roche Applied Science, Mannheim, Germany) in white 96-well plates (Roche, Cat. 
No. 04729692001) covered with instrument specific sealing foils. Each well contained 10 µL of 
following components: 5 µL of TaqMan 2x Universal PCR Master Mix No AmpErase UNG (Thermo 
Fisher, Applied Biosystems; PN 4324018), 3.5 µL of nuclease-free water, 0.5 µL of 20x miR-specific 
TaqMan MicroRNA Assay primer (Applied Biosystems, PN 4427975), and 1 µL of cDNA. The PCR 
run conditions were as follows: hot-start polymerase activation at 95 °C for 10 min, 45 amplification 
cycles with strand dissociation at 95 °C for 15 s, and annealing/elongation at 60 °C for 60 s with 
fluorescence acquisition, and a final cooling step at 40 °C for 60 s. The Cq values were extracted by 
the LightCycler 480 software v1.5 based on the "second derivative maximum" method and imported 
into a special data format in qBasePLUS Software v2.6 (Biogazelle, Zwijnaarde, Belgium) for 
statistical analysis. Three standard curves (miR-9-5p, miR-489-3p, and reference miR-103-3p) were 
generated with the LC480 software by 10-fold dilution steps over 7 logs of a 1:2 pre-diluted cDNA 
mixed with a 1:1000 pre-diluted amplicon. Because the efficiencies of all three standard curves ranged 
between 1.93 and 1.98, we recalculated a new standard curve with the input of all generated Cq values 
of measured three miRs. The overall standard curve had an efficiency of 1.95 (see the following 
section "Performance data of RT-qPCR analyses" with Figure S1). The linear dynamic range of the 
overall standard curve was between Cq 11.06 and Cq 35.24. All samples were in this measuring range. 
However, we defined a Cq value of 34.0 as lower limit for the quantification in the qBasePLUS 
software to achieve reliable expression data. The abovementioned qPCR efficiency value was used in 
qBasePLUS for the efficiency corrected calculation of the relative quantification. 
hsa-miR-223-3p MIMAT0000280 hsa-miR-223 002295 UGUCAGUUUGUCAAAUACCCCA 
Chr. X: 66018870 - 
66018979 [+] 
hsa-miR-342-3p MIMAT0000753 
hsa-miR-342-
3p 
002260 UCUCACACAGAAAUCGCACCCGU 
Chr.14: 100109655 
- 100109753 [+] 
hsa-miR-483-5p MIMAT0004761 
hsa-miR-483-
5p 
002338 AAGACGGGAGGAAAGAAGGGAG 
Chr.11: 2134134 - 
2134209 [−] 
hsa-miR-489-3p MIMAT0002805 hsa-miR-489 002358 GUGACAUCACAUAUACGGCAGC 
Chr. 7: 93483936 - 
93484019 [−] 
hsa-miR-500a-5p MIMAT0004773 hsa-miR-500 002428 UAAUCCUUGCUACCUGGGUGAGA 
Chr. X: 50008431 - 
50008514 [+] 
hsa-miR-885-5p MIMAT0004947 
hsa-miR-885-
5p 
002296 UCCAUUACACUACCCUGCCUCU 
Chr. 3: 10394489 - 
10394562 [−] 
hsa-miR-1269a MIMAT0005923 hsa-miR-1269 002789 CUGGACUGAGCCGUGCUACUGG 
Chr.4: 66276824 - 
66276928 [+] 
&hsa-miR-103a-
3p 
MIMAT0000101 hsa-miR-103 000439 AGCAGCAUUGUACAGGGCUAUGA 
Chr. 5: 168560896 
- 168560973 [−] 
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Performance data of the RT-qPCR analyses 
The performance data include the following figures and tables with the standard PCR curves 
(Supplementary Figure S1, reproducibility data (Supplementary Table S5), and correlation data 
between array data and RT-PCR results (Supplementary Figure 2).  
miR-
103a-3p 
 
Error: 0.0330 
Efficiency: 1.979 
Slope: −3.373 
y-Intercept: 10.61 
Link: 0.000 
miR-9-
5p 
 
Error: 0.0195 
Efficiency: 1.955 
Slope: −3.434 
y-Intercept: 10.22 
Link: 
0.00000880 
miR-
489-3p 
 
Error: 0.0214 
Efficiency: 1.934 
Slope: −3.491 
y-Intercept: 11.07 
Link: 
0.00000877 
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all miRs 
 
Error: 0.0282 
Efficiency: 1.950 
Slope: −3.447 
y-Intercept: 10.50 
Link: 0.000 
Figure S1. Characteristics of the standard curves of qPCR analyses Standard curves were generated 
either from diluted cDNAs or from diluted amplicons. Cq values were calculated by the LightCycler 
Software Version 1.5.0 using the "second derivative maximum" method. The efficiency, the slope, 
intercept, and error of the regression line were calculated by the LightCycler 480 software. The PCR-
efficiency is calculated by the LightCycler480 software after the formula: Efficiency=10-1/slope. 
According to the LightCycler 480 operator’s manual, the error value is the mean squared error of the 
single data points fit to the regression line. 
Supplementary Table S5. Reproducibility of miRNA measurements. 
Hsa-miR Concentrations Replicates (n) 
 Mean (SD) %RSD  
miR-9-5p    
level 1 9.995 (0.417) 4.18 4 
level 2 0.049 (0.003) 7.07 5 
miR-489-3p    
level 1 9.930 (0.377) 3.80 4 
level 2 0.091 (0.006) 6.52 5 
Abbreviation: %RSD = percent relative standard deviation. 
 
Supplementary Figure S2. Correlation between Array and RT-qPCR data of single miRNAs. The 
nine selected miRNAs examined in the validation phase showed strongly correlated Cq 
values in the two sample pools measured on the two platforms. 
Validation step: Droplet digital PCR with the QX200 digital PCR instrument  
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Details of the cDNA synthesis are described above. In addition to the brief description given in 
the Materials and Methods of the main text, we summarized here further methodical details 
(Supplementary Table S6, Supplementary Figure 3, and Supplementary Table 7) and analytical 
performance data of the droplet digital PCR (Supplementary Table S8) as well as miRNA expression 
data (Supplementary Figure S4, Supplementary Table S9) in relation to clinicopathological factors in 
order to support the results presented in the main text. 
Methodical details of the droplet digital PCR 
Methodical details are given in the following Supplementary Tables S6 and S7 and in 
Supplementary Figure S3. 
Table S6: Measurement conditions of droplet digital PCR analyses. 
Instrument 
QX200 ddPCR System (BIO-RAD, Germany, Munich) including following instruments (all from BIO-RAD): 
QX200 Droplet Generator 
PX1 PCR Plate Sealer 
T100 Thermal Cycler 
QX200 Droplet Reader 
Reagents 
2x ddPCR Supermix for Probes (no dUTP, BIO-RAD Cat. No. #186-3024) 
miR-specific Primer/Probes (TaqMan microRNA assays, Thermo Fisher Scientific, Applied Biosystems; Supp. Table S4) 
Experimental steps. 
1. Dispense 21 µL of ddPCR reaction mix (adjusted volume on pipet) up to the first hub of pipet (about 20 µL) 
without bubbles into the 8 sample-wells of the DG8 Cartridge (BIO-RAD Cat. No. #186-4008) 
2.  Add 70 µL of Droplet Generator Oil for Probes (BIO-RAD Cat. No. #186-3005) into the 8 oil-well of a DG8 
Cartridge (BIO-RAD Cat. No. #186-4008) 
3.  Cover cartridge with Droplet Generator DG8 Gasket (BIO-RAD Cat. No. #186-3009) and place the full cartridge 
into QX200 Droplet Generator (BIO-RAD) 
4.  Remove the cartridge from the Droplet Generator, remove the gasket and transfer 40 µL of droplets with a 8-
channel pipet (Pipet-Lite XLS, 5-50 µL LTS Rainin, Mettler-Toledo, Germany) into one column of a ddPCR 96-well 
plate (BIO-RAD, Cat. No #12001925) 
5.  Cover the 96-well plate with Pierceable Foil Heat Seal (BIO-RAD Cat. No. #181-4040) and insert the plate into heat 
block of the PX1 PCR plate sealer (BIO-RAD) and start the heat-sealing of 96-well plate with the foil for 5 s at 
180°C   
6.  Transfer the 96-well plate into the T100 Thermal Cycler (BIO-RAD) and start PCR run  
7.  After finishing PCR, transfer of 96-well plate into the QX200 Droplete Reader (BIO-RAD)  
8.  Read out of droplets per well with ddPCR Droplet Reader Oil (BIO-RAD Cat. No. #186-3004) and calculate copies 
of target miR/µL ddPCR reaction mix using QuantaSoft Software Version 1.7.4. (BIO-RAD) 
Pipetting scheme for 1x Reaction mix/sample:  
Volume (µL) Component 
11 2x ddPCR Supermix for Probes 
1.1 20x miR-specific primer/probe 
8.8 Nuclease free water 
1.1 miR-specific cDNA (diluted or undiluted) 
22 total volume of ddPCR reaction mix 
miR dependend volumes of cDNA were added 
Target miRNA µL cDNA (predilution)/22 µL ddPCR Reaction Mix ddPCR Cycle Number 
hsa-miR-9-5p 2.2 45 
hsa-miR-103a-3p 1 43 
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hsa-miR-203a-3p 1.1 40 
hsa-miR-204-5p  1.1 (1:2) 40 
hsa-miR-223-3p  1.1 (1:2) 40 
hsa-miR-489-3p  2.2 45 
hsa-miR-500a-5p  1.1 45 
hsa-miR-885-5p 1.1 40 
 (total volume cDNA + H2O = 9.9 µL per ddPCR mix)  
Thermal cycling steps for ddPCR run: 
Instrument: T100 Thermal Cycler (Bio-Rad Laboratories GmbH, Germany, Munich); Ramp rate: 2 °C/s before and after 
annealing step (1 min); lid: 105 °C 
Step Time  Temperature (°C) 
HOLD 10 min 95 
39-44x { 
30 s 94 
1 min 56 
HOLD 10 min 98 
HOLD ∞ 4 
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Gene name 
miRBase 
v.22 
AB 
assay 
ID 
Fluorescence amplitudes of positive and negative droplets/assay 
Mean number 
of accepted 
droplets/well 
%R
SD 
miR-9-5p 000583 
 
17352 9.6 
miR-103a-3p 000439 
 
 
16713 10.0 
miR-203a-3p 000507 
 
17434 7.5 
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Gene name 
miRBase 
v.22 
AB 
assay 
ID 
Fluorescence amplitudes of positive and negative droplets/assay 
Mean number 
of accepted 
droplets/well 
%R
SD 
miR-204-5p 000508 
 
 
18000 7.5 
miR-223-3p 002295 
 
 
17314 9.3 
miR-489-3p 002358 
 
 
17736 7.3 
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Gene name 
miRBase 
v.22 
AB 
assay 
ID 
Fluorescence amplitudes of positive and negative droplets/assay 
Mean number 
of accepted 
droplets/well 
%R
SD 
miR-500a-5p 002428 
 
16963 10.4 
miR-885-5p 002296 
 
 
17151 8.0 
Figure S3. Fluorescence scatter plots of the droplet digital PCR miRNA assays The blue clusters 
represent positive droplets with successful PCR amplification and the black clusters represent 
negative droplets without amplification. The threshold between positive and negative droplets can 
be set either automatically by the QuantaSoft software or manually (corresponding to the red line in 
the plot of miR-203a-3p, miR-500a-5p, and miR-885-5p). Outlier wells were indicated by the software 
with to many positive droplets, with quality score below 0.85 (corresponding with the drop volume 
of <0.85 nL) or wells with fewer than 10 000 droplets. The mean number of accepted droplets and 
%RSD was calculated using all measurements in this study. Abbreviation: %RSD = percent relative 
standard deviation. 
Table S7. Parameter λ given as median copies and interquartile range per partition for the measured 
miRNAs. λ was calculated as ratio of the estimated copy number in the total volume in all partitions 
(m) to the number of partitions (n). 
λ 
statistics 
per miR 
miR-9-
5p 
miR-103-
3p 
miR-203-
3p 
miR-204-
5p 
miR-223-
3p 
miR-489-
3p 
miR-500-
5p 
miR-885-
5p 
Median 0.0112 0.139 0.0055 0.0221 0.0284 0.0305 0.0153 0.0068 
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≠IQR = interquartile range. 
Performance data of the droplet digital PCR analyses 
Repeatability and reproducibility of measurements are presented as analytical performance data in the 
following Supplementary Table S8. 
Table S8. Repeatability and reproducibility data of ddPCR analyses. Repeatability data (A) were 
calculated as percent RSD values based on duplicate measurements of miR-103a-3p in this study. 
Reproducibility data (B) were calculated both for the copies of all miRNAs and the accepted droplets 
in their analyses using different levels of control materials. 
A. Repeatability data. 
miR-103a-3p Copy Number/µL Accepted Droplets/Well 
Sample size 126 126 
Overall mean 132.8 16662 
SD 6.57 798 
%RSD 4.95 4.79 
B. Reproducibility data. 
Hsa-miR 
Copy Number/µL Accepted Droplets/well Replicates 
Mean (SD) %RSD Mean (SD) %RSD (n) 
miR-9-5p      
level 1 1.7 (0.19) 11.3 17271 (1545) 8.9 4 
level 2 15.2 (1.09) 7.2 18104 (896) 4.9 5 
level 3 145.2 (6.42) 4.4 17663 (2454) 13.9 5 
miR-103a-3p      
level 1 96.6 (6.39) 6.6 17573 (955) 5.4 8 
miR-203a-3p      
level 1 3.6 (0.44) 12.1 18786 (903) 4.8 6 
level 2 13.4 (1.23) 9.2 18106 (589) 3.3 8 
miR-204-5p      
level 1 2.6 (0.40) 15.4 18002 (645) 3.6 6 
level 2 26.4 (2.61) 9.9 17396 (1346) 7.7 6 
miR-223-3p      
level 1 22.5 (1.76) 7.8 17334 (308) 1.8 4 
level 2 35.4 (2.99) 8.4 17827 (1396) 7.8 5 
miR-489-3p      
level 1 24.2 (1.15) 4.8 17386 (1328) 7.6 5 
level 2 106.0 (3.39) 3.2 17866 (294) 1.6 5 
miR-500a-5p      
level 1 7.2 (0.58) 8.0 17603 (1023) 5.8 6 
level 2 24.4 (1.40) 5.7 19083 (1035) 5.4 5 
miR-885-5p      
level 1 3.4 (0.51) 15.0 16916 (1131) 6.7 4 
level 2 22.0 (2.10) 9.6 18437 (1057) 5.7 5 
  
IQR≠ 
0.0039 to 
0.0371 
0.0754 to 
0.2020 
0.00215 to 
0.0140 
0.0035 to 
0.1063 
0.0134 to 
0.0546 
0.0194 to 
0.0775 
0.0072 to 
0.0291 
0.0042 to 
0.0209 
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Additional expression and correlation data 
 
Figure S4. Expression of selected miRNAs in tumor samples of RCC patients compared to normal 
adjacent renal parenchyma. Values were measured using droplet digital RT-PCR and are 
represented as medians with interquartile ranges of 60 tumor samples (T) and 45 samples 
from normal renal parenchyma distant from tumor (N). Significant differences between the 
sample groups were calculated by Mann-Whitney U test. 
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Table S9. Spearman rank correlations between pathological variables and miRNAs. Data were 
calculated with the total cohort as the correlation coefficients did not differ (p <0.100) between the 
responder and non-responder patients. 
Correlation between pathological 
variables and miRNAs 
miR-9-p 
miR-
203a-3p 
miR-
204-5p 
miR-
223-3p 
miR-
489-3p 
miR-
500a-5p 
miR-
885-5p 
pT stage 
Spearman RS 
p value 
0.092 
0.483 
-0.066 
0.617 
-0.183 
0.162 
0.103 
0.434 
0.080 
0.543 
-0.127 
0.332 
-0.075 
0.571 
Fuhrman 
grade 
Spearman RS 
p value 
0.324 
0.013 
0.008 
0.952 
-0.311 
0.017 
-0.179 
0.178 
-0.033 
0.808 
-0.125 
0.348 
-0.168 
0.207 
Metastatic 
status 
Spearman RS 
p value 
0.152 
0.245 
-0.046 
0.725 
0.015 
0.907 
0.012 
0.930 
-0.043 
0.742 
-0.109 
0.407 
-0.177 
0.177 
Table S10. List of the experimentally validated target genes of miR-9-5p taken from the databases 
miRTarBase [7], miRWalk2.0 [8], and Diana-Tarbase v.7.0 [9]. 
Gene EntrezID Chr Map Definition 
ABCC1 4363 16 16p13.1 ATP-binding cassette sub-family C CFTR/MRP member 1 
ACAA2 10449 18 18q21.1 acetyl-CoA acyltransferase 2 
ACADSB 36 10 10q26.13 acyl-CoA dehydrogenase short/branched chain 
ACAT1 38 11 11q22.3 acetyl-CoA acetyltransferase 1 
AGAP9 642517 10 10q11.22 ArfGAP with GTPase domain ankyrin repeat and PH domain 9 
AKR1B10 57016 7 7q33 aldo-keto reductase family 1 member B10 aldose reductase 
AKR1C8P 340811 10 10p15.1 aldo-keto reductase family 1, member C8, pseudogene 
ALDH1A3 220 15 15q26.3 aldehyde dehydrogenase 1 family member A3 
AMOTL1 154810 11 11q14.3 angiomotin like 1 
ANKFY1 51479 17 17p13.3 ankyrin repeat and FYVE domain containing 1 
ANP32B 10541 9 9q22.32 acidic leucine-rich nuclear phosphoprotein 32 family member B 
AP3B1 8546 5 5q14.1 adaptor-related protein complex 3 beta 1 subunit 
APBB2 323 4 4p13 amyloid beta A4 precursor protein-binding family B member 2 
ARHGEF10 9639 8 8p23 Rho guanine nucleotide exchange factor GEF 10 
ARL8B 55207 3 3p26.1 ADP-ribosylation factor-like 8B 
ATG10 83734 5 5q14.1 autophagy related 10 
ATL1 51062 14 14q22.1 atlastin GTPase 1 
ATP11C 286410 X Xq27.1 ATPase class VI type 11C 
ATP6V1C2 245973 2 NA ATPase H+ transporting lysosomal 42kDa V1 subunit C2 
ATP7A 538 X Xq21.1 ATPase Cu++ transporting alpha polypeptide 
ATXN7 6314 3 3p21.1-p12 ataxin 7 
AUH 549 9 9q22.31 AU RNA binding protein/enoyl-CoA hydratase 
AVIL 10677 12 12q14.1 advillin 
BACE1 23621 11 11q23.2-q23.3 beta-site APP-cleaving enzyme 1 
BCL2L11 10018 2 2q13 BCL2-like 11 apoptosis facilitator 
BCL6 604 3 3q27 B-cell CLL/lymphoma 6 
BIK 638 22 22q13.31 BCL2-interacting killer apoptosis-inducing 
BOD1L1 259282 4 4p16.1 biorientation of chromosomes in cell division 1-like 1 
C7orf31 136895 7 7p15.3 chromosome 7 open reading frame 31 
CA13 377677 8 8q21.2 carbonic anhydrase XIII 
CA8 767 8 8q12.1 carbonic anhydrase VIII 
CALML5 51806 10 10p15.1 calmodulin-like 5 
CAPZA1 829 1 1p13.2 capping protein actin filament muscle Z-line alpha 1 
CARD19 84270 9 9q22.31 caspase recruitment domain family member 19 
CCDC152 
10012979
2 
5 5p12 coiled-coil domain containing 152 
CCL19 6363 9 9p13 chemokine C-C motif ligand 19 
CCND1 595 11 11q13 cyclin D1 
CCNDBP1 23582 15 15q14-q15 cyclin D-type binding-protein 1 
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Gene EntrezID Chr Map Definition 
CCNG1 900 5 5q32-q34 cyclin G1 
CD34 947 1 1q32 CD34 molecule 
CD46 4179 1 1q32 CD46 molecule complement regulatory protein 
CDH1 999 16 16q22.1 cadherin 1 type 1 E-cadherin epithelial 
CDH3 1001 16 16q22.1 cadherin 3 type 1 P-cadherin placental 
CDH7 1005 18 18q22.1 cadherin 7 type 2 
CDK12 51755 17 17q12 cyclin-dependent kinase 12 
CDX2 1045 13 13q12.3 caudal type homeobox 2 
CERS2 29956 1 1q21.3 ceramide synthase 2 
CERS4 79603 19 19p13.2 ceramide synthase 4 
CHMP2B 25978 3 3p11.2 charged multivesicular body protein 2B 
CHMP3 51652 2 2p11.2 charged multivesicular body protein 3 
CHSY1 22856 15 15q26.3 chondroitin sulfate synthase 1 
CMKLR1 1240 12 12q24.1 chemokine-like receptor 1 
CMTM2 146225 16 16q21 CKLF-like MARVEL transmembrane domain containing 2 
CNOT6 57472 5 5q35.3 CCR4-NOT transcription complex subunit 6 
COL12A1 1303 6 6q12-q13 collagen type XII alpha 1 
COL6A5 256076 3 3q22.1 collagen type VI alpha 5 
COLEC12 81035 18 18p11.32 collectin sub-family member 12 
CPA4 51200 7 7q32 carboxypeptidase A4 
CPEB4 80315 5 5q21 cytoplasmic polyadenylation element binding protein 4 
CREB1 1385 2 2q34 cAMP responsive element binding protein 1 
CTHRC1 115908 8 8q22.3 collagen triple helix repeat containing 1 
CUEDC1 404093 17 17q23.2 CUE domain containing 1 
CXCR4 7852 2 2q21 chemokine C-X-C motif receptor 4 
CXXC5 51523 5 5q31.2 CXXC finger protein 5 
CYFIP2 26999 5 5q33.3 cytoplasmic FMR1 interacting protein 2 
CYP39A1 51302 6 6p21.1-p11.2 cytochrome P450 family 39 subfamily A polypeptide 1 
DICER1 23405 14 14q32.13 dicer 1 ribonuclease type III 
DMXL1 1657 5 5q22 Dmx-like 1 
DRD2 1813 11 11q23 dopamine receptor D2 
DSP 1832 6 6p24 desmoplakin 
E2F7 144455 12 12q21.2 E2F transcription factor 7 
EDEM3 80267 1 1q25 ER degradation enhancer mannosidase alpha-like 3 
EEF2K 29904 16 16p12.2 eukaryotic elongation factor-2 kinase 
EFCAB14 9813 1 1p33 EF-hand calcium binding domain 14 
EFNA1 1942 1 1q21-q22 ephrin-A1 
ELAVL1 1994 19 19p13.2 ELAV like RNA binding protein 1 
ELF3 1999 1 1q32.2 
E74-like factor 3 ets domain transcription factor epithelial-
specific 
EMC1 23065 1 1p36.13 ER membrane protein complex subunit 1 
EN2 2020 7 7q36 engrailed homeobox 2 
ENDOD1 23052 11 11q21 endonuclease domain containing 1 
EOGT 285203 3 3p14.1 
EGF domain-specific O-linked N-acetylglucosamine GlcNAc 
transferase 
EP300 2033 22 22q13.2 E1A binding protein p300 
ESR1 2099 6 6q25.1 estrogen receptor 1 
ETS1 2113 11 11q23.3 v-ets avian erythroblastosis virus E26 oncogene homolog 1 
F2 2147 11 11p11 coagulation factor II thrombin 
FAIM 55179 3 3q22.3 Fas apoptotic inhibitory molecule 
FAM46A 55603 6 6q14 family with sequence similarity 46 member A 
FAM73B 84895 9 9q34.11 family with sequence similarity 73 member B 
FBN2 2201 5 5q23-q31 fibrillin 2 
FERMT1 55612 20 20p12.3 fermitin family member 1 
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Gene EntrezID Chr Map Definition 
FERMT2 10979 14 14q22.1 fermitin family member 2 
FLNB 2317 3 3p14.3 filamin B beta 
FNBP1 23048 9 9q34 formin binding protein 1 
FOXO1 2308 13 13q14.1 forkhead box O1 
FOXO3 2309 6 6q21 forkhead box O3 
FOXP1 27086 3 3p14.1 forkhead box P1 
FRMD4A 55691 10 10p13 FERM domain containing 4A 
FRMD4B 23150 3 3p14.1 FERM domain containing 4B 
FSTL3 10272 19 19p13 follistatin-like 3 secreted glycoprotein 
GALNTL6 442117 4 4q34.1 polypeptide N-acetylgalactosaminyltransferase-like 6 
GFOD1 54438 6 6pter-p22.1 glucose-fructose oxidoreductase domain containing 1 
GIGYF1 64599 7 7q22 GRB10 interacting GYF protein 1 
GIP 2695 17 17q21.3-q22 gastric inhibitory polypeptide 
GNAT2 2780 1 1p13.1 
guanine nucleotide binding protein G protein alpha 
transducing activity polypeptide 2 
GPBP1L1 60313 1 1p34.1 GC-rich promoter binding protein 1-like 1 
GRN 2896 17 17q21.32 granulin 
HBP1 26959 7 7q22-q31 HMG-box transcription factor 1 
HDAC4 9759 2 2q37.3 histone deacetylase 4 
HIST1H2AE 3012 6 6p22.1 histone cluster 1 H2ae 
HIST1H2AI 8329 6 6p22.1 histone cluster 1 H2ai 
HIST1H3F 8968 6 6p22.2 histone cluster 1 H3f 
HIST1H4H 8365 6 6p22.1 histone cluster 1 H4h 
HIST2H2AC 8338 1 1q21.2 histone cluster 2 H2ac 
HLA-A 3105 6 6p21.3 major histocompatibility complex class I A 
HN1L 90861 16 16p13.3 hematological and neurological expressed 1-like 
HOXC12 3228 12 12q13.13 homeobox C12 
HTR3A 3359 11 11q23.1 5-hydroxytryptamine serotonin receptor 3A ionotropic 
ID2 3398 2 2p25 
inhibitor of DNA binding 2 dominant negative helix-loop-helix 
protein 
ID4 3400 6 6p22.3 
inhibitor of DNA binding 4 dominant negative helix-loop-helix 
protein 
IDS 3423 X Xq28 iduronate 2-sulfatase 
IGF2R 3482 6 6q26 insulin-like growth factor 2 receptor 
IL5 3567 5 5q31.1 interleukin 5 
IPO7 10527 11 11p15.4 importin 7 
IPPK 64768 9 9q22.31 inositol 13456-pentakisphosphate 2-kinase 
IREB2 3658 15 15q25.1 iron-responsive element binding protein 2 
ITGB3BP 23421 1 1p31.3 integrin beta 3 binding protein beta3-endonexin 
JAK1 3716 1 1p32.3-p31.3 Janus kinase 1 
KCNJ15 3772 21 21q22.2 potassium inwardly-rectifying channel subfamily J member 15 
KCNJ2 3759 17 17q24.3 potassium inwardly-rectifying channel subfamily J member 2 
KIAA1468 57614 18 18q21.33 KIAA1468 
KIF1A 547 2 2q37.3 kinesin family member 1A 
KIF1B 23095 1 1p36.2 kinesin family member 1B 
KIF1C 10749 17 17p13.2 kinesin family member 1C 
KLF17 128209 1 1p34.1 Kruppel-like factor 17 
KLF5 688 13 13q22.1 Kruppel-like factor 5 intestinal 
KLF6 1316 10 10p15 Kruppel-like factor 6 
KLRC1 3821 12 12p13 killer cell lectin-like receptor subfamily C member 1 
KLRK1 22914 12 12p13.2-p12.3 killer cell lectin-like receptor subfamily K member 1 
KMT2D 8085 12 12q13.12 lysine K-specific methyltransferase 2D 
LDLRAP1 26119 1 1p36-p35 low density lipoprotein receptor adaptor protein 1 
LHFPL2 10184 5 5q14.1 lipoma HMGIC fusion partner-like 2 
LMNA 4000 1 1q22 lamin A/C 
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LPPR2 64748 19 19p13.2 lipid phosphate phosphatase-related protein type 2 
LPXN 9404 11 11q12.1 leupaxin 
LRP1 4035 12 12q13.3 low density lipoprotein receptor-related protein 1 
LRRC15 131578 3 3q29 leucine rich repeat containing 15 
LRRTM1 347730 2 2p12 leucine rich repeat transmembrane neuronal 1 
MAGEA2B 266740 X Xq28 melanoma antigen family A 2B 
MALAT1 378938 11 11q13.1 
metastasis associated lung adenocarcinoma transcript 1 (non-
protein coding) 
MAP1B 4131 5 5q13 microtubule-associated protein 1B 
MAP3K3 4215 17 17q23.3 mitogen-activated protein kinase kinase kinase 3 
MAP3K8 1326 10 10p11.23 mitogen-activated protein kinase kinase kinase 8 
MCC 4163 5 5q21 mutated in colorectal cancers 
MDM4 4194 1 1q32 MDM4 p53 regulator 
MESDC1 59274 15 15q13 mesoderm development candidate 1 
MKX 283078 10 10p12.1 mohawk homeobox 
MMP13 4322 11 11q22.3 matrix metallopeptidase 13 collagenase 3 
MMP2 4313 16 16q13-q21 
matrix metallopeptidase 2 gelatinase A 72kDa gelatinase 72kDa 
type IV collagenase 
MMP9 4318 20 20q11.2-q13.1 
matrix metallopeptidase 9 gelatinase B 92kDa gelatinase 92kDa 
type IV collagenase 
MN1 4330 22 22q12.1 meningioma disrupted in balanced translocation 1 
MORF4L1 10933 15 15q24 mortality factor 4 like 1 
MSR1 4481 8 8p22 macrophage scavenger receptor 1 
MTHFD1 4522 14 14q24 
methylenetetrahydrofolate dehydrogenase NADP+ dependent 
1 methenyltetrahydrofolate cyclohydrolase 
formyltetrahydrofolate synthetase 
MTHFD2 10797 2 2p13.1 
methylenetetrahydrofolate dehydrogenase NADP+ dependent 
2 methenyltetrahydrofolate cyclohydrolase 
MTL5 9633 11 11q13.2-q13.3 metallothionein-like 5 testis-specific tesmin 
MTX3 345778 5 5q14.1 metaxin 3 
MYF6 4618 12 12q21 myogenic factor 6 herculin 
MYH9 4627 22 22q13.1 myosin heavy chain 9 non-muscle 
MYLK 4638 3 3q21 myosin light chain kinase 
NAV1 89796 1 1q32.3 neuron navigator 1 
NBEA 26960 13 13q13 neurobeachin 
NCOR2 9612 12 12q24 nuclear receptor corepressor 2 
NF1 4763 17 17q11.2 neurofibromin 1 
NFAT5 10725 16 16q22.1 nuclear factor of activated T-cells 5 tonicity-responsive 
NFATC3 4775 16 16q22.2 
nuclear factor of activated T-cells cytoplasmic calcineurin-
dependent 3 
NFKB1 4790 4 4q24 
nuclear factor of kappa light polypeptide gene enhancer in B-
cells 1 
NIN 51199 14 14q22.1 ninein GSK3B interacting protein 
NIPA1 123606 15 15q11.2 non imprinted in Prader-Willi/Angelman syndrome 1 
NKX2-2 4821 20 20p11.22 NK2 homeobox 2 
NMNAT2 23057 1 1q25 nicotinamide nucleotide adenylyltransferase 2 
NPY4R 5540 10 10q11.2 neuropeptide Y receptor Y4 
NR2E1 7101 6 6q21 nuclear receptor subfamily 2 group E member 1 
NR6A1 2649 9 9q33.3 nuclear receptor subfamily 6 group A member 1 
NRIP3 56675 11 11p15.3 nuclear receptor interacting protein 3 
NSUN7 79730 4 4p14 NOP2/Sun domain family member 7 
NTRK3 4916 15 15q25 neurotrophic tyrosine kinase receptor type 3 
NUDT19 390916 19 19q13.11 nudix nucleoside diphosphate linked moiety X-type motif 19 
NUP155 9631 5 5p13.1 nucleoporin 155kDa 
OAF 220323 11 11q23.3 OAF homolog Drosophila 
OLR1 4973 12 12p13.2-p12.3 oxidized low density lipoprotein lectin-like receptor 1 
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ONECUT2 9480 18 18q21.31 one cut homeobox 2 
OPTN 10133 10 10p13 optineurin 
P4HA2 8974 5 5q31 prolyl 4-hydroxylase alpha polypeptide II 
PACS1 55690 11 11q13.1-q13.2 phosphofurin acidic cluster sorting protein 1 
PAX1 5075 20 20p11.2 paired box 1 
PCMTD2 55251 20 20q13.33 
protein-L-isoaspartate D-aspartate O-methyltransferase domain 
containing 2 
PDZK1 5174 1 1q21 PDZ domain containing 1 
PELP1 27043 17 17p13.2 proline glutamate and leucine rich protein 1 
PI4K2A 55361 10 10q24 phosphatidylinositol 4-kinase type 2 alpha 
PIGB 9488 15 15q21.3 phosphatidylinositol glycan anchor biosynthesis class B 
PIGM 93183 1 1q23.2 phosphatidylinositol glycan anchor biosynthesis class M 
PLCB4 5332 20 20p12 phospholipase C beta 4 
PLEKHB1 58473 11 11q13.5-q14.1 
pleckstrin homology domain containing family B evectins 
member 1 
PNRC2 55629 1 1p36.11 proline-rich nuclear receptor coactivator 2 
POGZ 23126 1 1q21.3 pogo transposable element with ZNF domain 
POU2F1 5451 1 1q24.2 POU class 2 homeobox 1 
POU2F2 5452 19 19q13.2 POU class 2 homeobox 2 
PPAP2A 8611 5 5q11 phosphatidic acid phosphatase type 2A 
PPARA 5465 22 22q13.31 peroxisome proliferator-activated receptor alpha 
PPP4R2 151987 3 3p13 protein phosphatase 4 regulatory subunit 2 
PQLC3 130814 2 2p25.1 PQ loop repeat containing 3 
PRDM1 639 6 6q21 PR domain containing 1 with ZNF domain 
PRG4 10216 1 1q25-q31 proteoglycan 4 
PRKD3 23683 2 2p21 protein kinase D3 
PRRX1 5396 1 1q24 paired related homeobox 1 
PRTG 283659 15 15q21.3 protogenin 
PTPRK 5796 6 6q22.2-q22.3 protein tyrosine phosphatase receptor type K 
PXDN 7837 2 2p25 peroxidasin homolog Drosophila 
QARS 5859 3 3p21.31 glutaminyl-tRNA synthetase 
RAB34 83871 17 17q11.2 RAB34 member RAS oncogene family 
RAB8B 51762 15 15q22.2 RAB8B member RAS oncogene family 
RABGAP1 23637 9 9q34.11 RAB GTPase activating protein 1 
RASSF8 11228 12 12p12.3 
Ras association RalGDS/AF-6 domain family N-terminal 
member 8 
RBFOX2 23543 22 22q13.1 RNA binding protein fox-1 homolog C. elegans 2 
RCC2 55920 1 1p36.13 regulator of chromosome condensation 2 
REST 5978 4 4q12 RE1-silencing transcription factor 
RHAG 6005 6 6p12.3 Rh-associated glycoprotein 
RHOH 399 4 4p13 ras homolog family member H 
RHOV 171177 15 15q13.3 ras homolog family member V 
RNF103-
CHMP3 
10052676
7 
2 2p RNF103-CHMP3 readthrough 
RNF146 81847 6 6q22.1-q22.33 ring finger protein 146 
RNF44 22838 5 5q35.2 ring finger protein 44 
RYBP 23429 3 3p13 RING1 and YY1 binding protein 
SCD5 79966 4 4q21.22 stearoyl-CoA desaturase 5 
SDC1 6382 2 2p24.1 syndecan 1 
SEC23IP 11196 10 10q25-q26 SEC23 interacting protein 
SERAC1 84947 6 6q25.3 serine active site containing 1 
SERINC5 256987 5 5q14.1 serine incorporator 5 
SERPINB9 5272 6 6p25 serpin peptidase inhibitor clade B ovalbumin member 9 
SERPINH1 871 11 11q13.5 
serpin peptidase inhibitor clade H heat shock protein 47 
member 1 collagen binding protein 1 
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SFT2D2 375035 1 1q24.2 SFT2 domain containing 2 
SIRT1 23411 10 10q21.3 sirtuin 1 
SLC19A3 80704 2 2q37 solute carrier family 19 thiamine transporter member 3 
SLC22A3 6581 6 6q25.3 solute carrier family 22 organic cation transporter member 3 
SLC22A5 6584 5 5q23.3 
solute carrier family 22 organic cation/carnitine transporter 
member 5 
SLC25A30 253512 13 13q14.13 solute carrier family 25 member 30 
SLC2A5 6518 1 1p36.2 
solute carrier family 2 facilitated glucose/fructose transporter 
member 5 
SLC30A4 7782 15 15q21.1|15q21.1 solute carrier family 30 zinc transporter member 4 
SLC35B3 51000 6 6p24.3 
solute carrier family 35 adenosine 3'-phospho 5'-phosphosulfate 
transporter member B3 
SLC35E2 9906 1 1p36.33 solute carrier family 35 member E2 
SLC39A14 23516 8 8p21.3 solute carrier family 39 zinc transporter member 14 
SLC7A2 6542 8 8p22 
solute carrier family 7 cationic amino acid transporter y+ system 
member 2 
SMARCA1 6594 X Xq25 
SWI/SNF related matrix associated actin dependent regulator of 
chromatin subfamily a member 1 
SMU1 55234 9 9p12 smu-1 suppressor of mec-8 and unc-52 homolog C. elegans 
SNAI2 6591 8 8q11 snail family zinc finger 2 
SNX7 51375 1 1p21.3 sorting nexin 7 
SOCS5 9655 2 2p21 suppressor of cytokine signaling 5 
SOD2 6648 6 6q25.3 superoxide dismutase 2 mitochondrial 
SPAG9 9043 17 17q21.33 sperm associated antigen 9 
SPI1 6688 11 11p11.2 spleen focus forming virus SFFV proviral integration oncogene 
SPON2 10417 4 4p16.3 spondin 2 extracellular matrix protein 
SPTBN1 6711 2 2p21 spectrin beta non-erythrocytic 1 
SRF 6722 6 6p21.1 
serum response factor c-fos serum response element-binding 
transcription factor 
STK3 6788 8 8q22.2 serine/threonine kinase 3 
STMN1 3925 1 1p36.11 stathmin 1 
STX6 10228 1 1q25.3 syntaxin 6 
SUMF2 25870 7 7q11.1 sulfatase modifying factor 2 
SUMO1 7341 2 2q33 small ubiquitin-like modifier 1 
SYAP1 94056 X Xp22.2 synapse associated protein 1 
SYNE1 23345 6 6q25 spectrin repeat containing nuclear envelope 1 
SYNE2 23224 14 14q23.2 spectrin repeat containing nuclear envelope 2 
SYNGR2 9144 17 17q25.3 synaptogyrin 2 
SYPL1 6856 7 7q22.3 synaptophysin-like 1 
TAGLN 6876 11 11q23.2 transgelin 
TAL1 6886 1 1p32 T-cell acute lymphocytic leukemia 1 
TAOK1 57551 17 17q11.2 TAO kinase 1 
TBC1D9 23158 4 4q31.21 TBC1 domain family member 9 with GRAM domain 
TBPL1 9519 6 6q22.1-q22.3 TBP-like 1 
TC2N 123036 14 14q32.12 tandem C2 domains nuclear 
TCL1B 9623 14 14q32.1 T-cell leukemia/lymphoma 1B 
TESK2 10420 1 1p32 testis-specific kinase 2 
TFRC 7037 3 3q29 transferrin receptor 
TGFBI 7045 5 5q31 transforming growth factor beta-induced 68kDa 
TGFBR2 7048 3 3p22 transforming growth factor beta receptor II 70/80kDa 
TMEM216 51259 11 11q13.1 transmembrane protein 216 
TMEM245 23731 9 9q31 transmembrane protein 245 
TRAK2 66008 2 2q33 trafficking protein kinesin binding 2 
TRIM14 9830 9 9q22.33 tripartite motif containing 14 
TRMT13 54482 1 1p21.2 tRNA methyltransferase 13 homolog S. cerevisiae 
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TRPM7 54822 15 15q21 
transient receptor potential cation channel subfamily M 
member 7 
TRRAP 8295 7 7q21.2-q22.1 transformation/transcription domain-associated protein 
TTC7B 145567 14 14q32.11 tetratricopeptide repeat domain 7B 
TWISTNB 221830 7 7p21.1 TWIST neighbor 
UBE4B 10277 1 1p36.3 ubiquitination factor E4B 
UGDH 7358 4 4p15.1 UDP-glucose 6-dehydrogenase 
UHMK1 127933 1 1q23.3 U2AF homology motif UHM kinase 1 
UMPS 7372 3 3q13 uridine monophosphate synthetase 
VAMP5 10791 2 2p11.2 vesicle-associated membrane protein 5 
VEGFA 7422 6 6p12 vascular endothelial growth factor A 
VIM 7431 10 10p13 vimentin 
VPS8 23355 3 3q27.2 vacuolar protein sorting 8 homolog S. cerevisiae 
WDR70 55100 5 5p13.2 WD repeat domain 70 
WNT6 7475 2 2q35 wingless-type MMTV integration site family member 6 
WNT8A 7478 5 5q31 wingless-type MMTV integration site family member 8A 
XRN2 22803 20 20p11.2-p11.1 5'-3' exoribonuclease 2 
ZBED3 84327 5 5q13.3 zinc finger BED-type containing 3 
ZFAND1 79752 8 8q21.13 zinc finger AN1-type domain 1 
ZMAT4 79698 8 8p11.21 zinc finger matrin-type 4 
ZNF407 55628 18 18q23 zinc finger protein 407 
ZNF557 79230 19 19p13.2 zinc finger protein 557 
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